Investors are lining up to oppose pay-and-perks plan for Pascal Soriot worth up to £17.8m for 2021
AstraZeneca could be forced to rip up plans to boost the pay of its chief executive, Pascal Soriot, as investors prepare to vote on proposals that could take his remuneration after nearly a decade at the helm of the pharmaceutical company past £100m.
A host of shareholder advisory groups and fund managers have lined up to oppose a pay-and-perks plan with a maximum value of £17.8m for 2021. If investors holding more than 50% of the company’s stock vote against the proposals at its annual meeting on Tuesday, AstraZeneca will be forced to redraw the scheme.
